Background:Galectin-3 (Gal-3) plays a role in the mechanisms underlying ocular venous malformation.We conducted this study to investigate the effect of pingyangmycin pretreatment on the Gal-3 expressions and biolog...Background:Galectin-3 (Gal-3) plays a role in the mechanisms underlying ocular venous malformation.We conducted this study to investigate the effect of pingyangmycin pretreatment on the Gal-3 expressions and biological behavior of ocular venous malformation.Methods:Tissue samples were collected from 136 patients with ocular venous malformation.Patients were randomly divided into pingyangmycin (n =69) and nonpingyangmycin group (n 67).Patients in the pingyangmycin group received a local injection of 0.02% pingyangmycin once every 2 days for 2 weeks (7 doses) before removal surgery,whereas patients in the nonpingyangmycin group underwent removal surgery without local injection.The protein and messenger RNA (mRNA) expression of Gal-3 were detected by using immunohistochemistry and in situ hybridization.Results:Gal-3 protein was expressed in 35 (52%) of 67 samples in the nonpingyangmycin group and in 19 (28%) of 69 samples in the pingyangmycin group (P 〈 0.05).Gal-3 mRNA expression was detected in 39 (58%) of 67 samples in the nonpingyangmycin group and 22 (32%) of 69 samples in the pingyangmycin group (P 〈 0.05).The higher Gal-3 expressions were detected in samples with deeper invasiveness than those with superficial invasiveness before (χ^2=12.720 and 13.369,respectively,both P 〈 0.05) and after pingyangmycin treatment (χ^2=8.429 and 4.590,respectively,both P 〈 0.05).It was more frequently detected in mesh-like lesions with unclear boundary than round lesions with clear boundary before (χ^2= =30.291 and 41.466,respectively,both P 〈 0.05) and after pingyangmycin treatment (χ^2= =14.619 and 15.130,respectively,both P 〈 0.05).Pingyangmycin treatment led to a significant difference in Gal-3 expressions at both protein and mRNA levels (χ^2==8.664 and 9.524,respectively,both P 〈 0.05).Conclusions:Gal-3 expression may be involved in the development and invasiveness of ocular venous malformation,and pingyangmycin can inhibit Gal-3 expression,indicating a role of pingyangmycin treatment before the removal of ocular venous malformation.展开更多
According to a new international classification of vascular lesions, venous vascular malformation has become the most common type of congenital vascular malformation. A characteristic of this disease is its life-long ...According to a new international classification of vascular lesions, venous vascular malformation has become the most common type of congenital vascular malformation. A characteristic of this disease is its life-long progressive development, which is the main cause of harm to health and is different from hemangioma. Severe hemangioma with thrombocytopenia (Kasabach-Merritt syndrome) is often encountered in children, especially in infants younger than 1 year old. Coagulation abnormalities in Kasabach-Merritt syndrome are mainly caused by increased platelet destruction. Whereas, severe venous malformation-associated coagulopathy is attributed to the depletion of coagulation substances and extensive intravenous coagulation, and it occurs in adults. In principle, surgery is required.展开更多
文摘Background:Galectin-3 (Gal-3) plays a role in the mechanisms underlying ocular venous malformation.We conducted this study to investigate the effect of pingyangmycin pretreatment on the Gal-3 expressions and biological behavior of ocular venous malformation.Methods:Tissue samples were collected from 136 patients with ocular venous malformation.Patients were randomly divided into pingyangmycin (n =69) and nonpingyangmycin group (n 67).Patients in the pingyangmycin group received a local injection of 0.02% pingyangmycin once every 2 days for 2 weeks (7 doses) before removal surgery,whereas patients in the nonpingyangmycin group underwent removal surgery without local injection.The protein and messenger RNA (mRNA) expression of Gal-3 were detected by using immunohistochemistry and in situ hybridization.Results:Gal-3 protein was expressed in 35 (52%) of 67 samples in the nonpingyangmycin group and in 19 (28%) of 69 samples in the pingyangmycin group (P 〈 0.05).Gal-3 mRNA expression was detected in 39 (58%) of 67 samples in the nonpingyangmycin group and 22 (32%) of 69 samples in the pingyangmycin group (P 〈 0.05).The higher Gal-3 expressions were detected in samples with deeper invasiveness than those with superficial invasiveness before (χ^2=12.720 and 13.369,respectively,both P 〈 0.05) and after pingyangmycin treatment (χ^2=8.429 and 4.590,respectively,both P 〈 0.05).It was more frequently detected in mesh-like lesions with unclear boundary than round lesions with clear boundary before (χ^2= =30.291 and 41.466,respectively,both P 〈 0.05) and after pingyangmycin treatment (χ^2= =14.619 and 15.130,respectively,both P 〈 0.05).Pingyangmycin treatment led to a significant difference in Gal-3 expressions at both protein and mRNA levels (χ^2==8.664 and 9.524,respectively,both P 〈 0.05).Conclusions:Gal-3 expression may be involved in the development and invasiveness of ocular venous malformation,and pingyangmycin can inhibit Gal-3 expression,indicating a role of pingyangmycin treatment before the removal of ocular venous malformation.
文摘According to a new international classification of vascular lesions, venous vascular malformation has become the most common type of congenital vascular malformation. A characteristic of this disease is its life-long progressive development, which is the main cause of harm to health and is different from hemangioma. Severe hemangioma with thrombocytopenia (Kasabach-Merritt syndrome) is often encountered in children, especially in infants younger than 1 year old. Coagulation abnormalities in Kasabach-Merritt syndrome are mainly caused by increased platelet destruction. Whereas, severe venous malformation-associated coagulopathy is attributed to the depletion of coagulation substances and extensive intravenous coagulation, and it occurs in adults. In principle, surgery is required.